It’s only fair to share… Lasmotinib CAS 2127107-15-5 MF C19H19FN4O2S MW386.4 g/mol 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide 3-(carbamoylamino)-5-[(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamidetyrosine kinase inhibitor, antineoplastic, PHI-101, PHI 101, U2UY9TBQ8Z Lasmotinib (also known by its research code PHI-101) is a next-generation, orally bioavailable targeted cancer therapy. It functions as a dual FLT3 and CHK2 inhibitor. It is primarily being investigated to treat Acute Myeloid Leukemia …